# Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

> **NCT03035331** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 11 (actual)

## Conditions studied

- Aggressive Non-Hodgkin Lymphoma
- Indolent Non-Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Recurrent T-Cell Non-Hodgkin Lymphoma
- Small Lymphocytic Lymphoma

## Interventions

- **PROCEDURE:** Cryosurgery
- **BIOLOGICAL:** Dendritic Cell Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Pneumococcal 13-valent Conjugate Vaccine
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT03035331
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-15
- **Primary completion:** 2022-01-25
- **Final completion:** 2022-09-10
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03035331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03035331, "Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03035331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*